北京瑞强律师事务所 关于陕西盘龙药业集团股份有限公司 2024 年年度股东会 之 法律意见书 二零二五年五月 0 地 址：北京市东城区东长安街 1 号 东方广场 W2 座 1004-05 室 电 话：010-58116099 传 真：010-58116099 Email：Recher@bjrecher.com 北京瑞强律师事务所 关于陕西盘龙药业集团股份有限公司 2024 年年度股东会 之 法律意见书 北京瑞强律师事务所（以下简称"本所"）接受陕西盘龙药业集团股份有限 公司（以下简称"公司"）的委托，指派本所陈晓昀律师、王志恒律师出席公司 于 2025 年 5 月 16 日下午 14:00 在陕西省西安市灞桥区现代纺织产业园灞柳二路 2801 号陕西盘龙医药股份有限公司二楼会议室召开的 2024 年年度股东会（以下 简称"本次股东会"）。现依据《中华人民共和国公司法》（以下简称"《公司 法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《深圳证券交 易所上市公司股东会网络投票实施细则》（以下简称"《网络投票细则》"）《上 市公司股东会规则》（以下简称"《股东会规则》"）等法律、行政法规、其他 规范性文 ...

届时，公司董事长及相关高级管理人员将通过互动平台与投资者进行网络沟通和交流，欢迎广大投资者 踊跃参加！ 活动时间：2025年5月20日 15:00-17:00 活动地址："全景路演" 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002864 证券简称：盘龙药业 公告编号：2025-024 陕西盘龙药业集团股份有限公司 关于参加"2025年陕西辖区上市公司投资者 集体接待日暨 2024年度业绩说明会"的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 为促进上市公司规范运作、健康发展，增强上市公司信息透明度，加强与广大投资者沟通交流，进一步 提升投资者关系管理水平，陕西上市公司协会根据陕西证监局工作部署，联合深圳市全景网络有限公司 举办"2025年陕西辖区上市公司投资者集体接待日暨2024年度业绩说明会"。 网址：https://rs.p5w.net/ 为充分尊重投资者、提升交流的针对性，公司现就2024年度业绩说明会提前向投资者公开征集问题，广 泛听取投资者的意见和建议。投资者可提前访问网址https://ir.p5w.net/zj，进入问 ...

为促进上市公司规范运作、健康发展，增强上市公司信息透明度，加强与广 大投资者沟通交流，进一步提升投资者关系管理水平，陕西上市公司协会根据陕 西证监局工作部署，联合深圳市全景网络有限公司举办"2025 年陕西辖区上市公 司投资者集体接待日暨 2024 年度业绩说明会"。 届时，公司董事长及相关高级管理人员将通过互动平台与投资者进行网络沟 通和交流，欢迎广大投资者踊跃参加！ 活动时间：2025 年 5 月 20 日 15:00-17:00 活动地址："全景路演" 证券代码：002864 证券简称：盘龙药业 公告编号：2025-024 陕西盘龙药业集团股份有限公司 关于参加"2025 年陕西辖区上市公司投资者集体接待日暨 2024 年度业绩说明会"的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 网址：https://rs.p5w.net/ 为充分尊重投资者、提升交流的针对性，公司现就 2024 年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可提前访问网址 https://ir.p5w.net/zj，进入问题征集专题页面，选择本公 ...

证券代码：002864 证券简称：盘龙药业 公告编号：2025-023 陕西盘龙药业集团股份有限公司 关于召开 2024 年年度股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日在巨潮 资讯网上披露了《关于召开 2024 年年度股东会的通知》，现将本次年度股东会的有关 事项提示如下： 一、召开会议的基本情况 1.股东会届次：2024 年年度股东会； 2.股东会的召集人：公司董事会； 3.会议召开的合法、合规性：经公司第四届董事会第二十四次会议审议通过，决定 召开公司 2024 年年度股东会，本次会议的召开符合《中华人民共和国公司法》《上市 公司股东会规则》《深圳证券交易所股票上市规则》等有关法律法规及《公司章程》的 规定。 4.会议召开的日期、时间： （1）现场会议召开日期：2025 年 5 月 16 日（星期五）下午 14:00； （2）网络投票时间为：2025 年 5 月 16 日；其中，通过深圳证券交易所交易系统进 行网络投票的具体时间为：2025 年 5 ...

Group 1: Financial Performance - The company's net profit for the current period is 120.27 million yuan, an increase of 9.84 million yuan year-on-year, with a net profit margin of 12.35%, up by 1.09% [8] - Operating revenue decreased by 0.71% year-on-year, while the net profit increased by 8.91%, indicating a divergence in revenue and profit growth due to changes in product structure [22][14] - The company’s operating cash flow net amount increased by 50.50% year-on-year, primarily due to stable cash flow from self-produced traditional Chinese medicine [9] Group 2: Market Position and Product Performance - The main product, Panlong Qipian, holds the number one market share in the traditional Chinese medicine market for musculoskeletal and rheumatic diseases, with a market share of 8.05% [2][11] - The company’s revenue from the Northwest region decreased by 32.48%, attributed to the concentration of clients in that area and the impact of divesting a subsidiary [5] - The company plans to expand its product line and market presence, focusing on potential high-revenue products like children's throat granules and osteoporosis tablets [11] Group 3: Research and Development - R&D expenses increased by 85.31% year-on-year, with a total of 17.28 million yuan invested, but the R&D expense ratio remains low at 3.8% compared to the industry average [10] - The company is advancing the development of new products, including PLZY-001 and PLJT-004, and aims to enhance its R&D capabilities through partnerships with universities and research institutions [4][6] - The company has established multiple research platforms to support innovation in traditional Chinese medicine, including a new drug research base in Shaanxi [6] Group 4: Strategic Initiatives - The company adheres to a "one body, two wings" strategy, focusing on core business and innovation while expanding its international vision [6] - Plans to enhance the market presence of traditional Chinese medicine products and improve brand recognition in key markets are underway [7] - The company is committed to sustainable practices and has been recognized as a national green factory, integrating environmental considerations into its operations [16] Group 5: Challenges and Risks - The company faces risks related to the concentration of revenue sources, particularly from its core product, Panlong Qipian, which accounts for over 70% of revenue [11] - The increase in accounts receivable, which is three times the profit, raises concerns about potential bad debt risks, although historical data suggests minimal losses [5] - The company is addressing the challenges posed by fluctuating raw material prices and healthcare cost control policies through strategic sourcing and inventory management [12]

Core Viewpoint - The performance meeting of Panlong Pharmaceutical for the year 2024 highlighted the company's steady growth, innovative strategies, and commitment to social responsibility, with a focus on traditional Chinese medicine and modern pharmaceutical development [1][4][9]. Financial Performance - In 2024, Panlong Pharmaceutical achieved a revenue of 974 million yuan and a net profit attributable to shareholders of 120 million yuan, representing a year-on-year growth of 8.91% [7]. - The sales revenue of the leading products experienced double-digit growth, while the plant medicine sector saw a three-digit increase [7]. Product Development and Innovation - The company has made significant advancements in research and development, particularly in new traditional Chinese medicine, chemical drugs, and medical institution formulations [7]. - The self-developed innovative traditional Chinese medicine PLZY-001 is accelerating clinical exploration, and several chemical generic drugs have successfully completed pilot tests [7]. - The establishment of the Panlong Xinyuan (Guangdong) New Drug Research and Transformation Base in the Guangdong-Hong Kong-Macao Greater Bay Area aims to enhance innovation capabilities [7]. Strategic Vision and Future Plans - The company plans to increase cash dividends to shareholders, proposing a cash dividend of 31.77 million yuan, which accounts for 26.42% of net profit [9]. - The strategic vision includes becoming a leader in the field of wind and bone injury medications and a specialist in chronic pain management, with a focus on a comprehensive development strategy [9]. - The company aims to enhance its governance and operational efficiency through a specialized and compliant marketing organization and a robust research and development system [9][11].

在创新药研发方面，2024年公司在原有的"四个三"科研平台的基础上，新获批陕西省中医药制剂及新药 研发中试基地、中药健康产品技术联合攻关研发转化与产业协同发展国际研究基地、陕西省创新药物研 究中心等5个科研平台；此外，全资子公司健康控股拟与博济医药全资子公司广济投资共同出资在广州 市黄埔区设立合资公司盘龙杏林（广东）新药研究有限公司，未来合资公司将充分发挥双方优势，专注 于一系列中药创新药的立项研发，聚焦公司核心大品种、发力慢病创新药，稳步建立现代中药创新梯 队。研发投入持续增加，2024年研发投入同比增长85.31%，重点研究项目顺利推进。 在医保改革和价格治理方面，目前公司主营产品盘龙七片为独家专利中成药、医保甲类产品，价格体系 稳定，盘龙七片入选七部国家级临床诊疗指南、三个专家共识、三本国家级重点教材和一本临床路径释 义，同时被推荐为临床用药。面对市场环境变化，公司将持续深化盘龙七片产品循证研究，提升产品自 身优势特性，调整终端市场竞争策略，积极开发县级空白市场，加快小儿咽扁颗粒、骨松宝片等未来过 亿元潜力产品的市场发展培育，实现多品增销和临床、零售双轮销售驱动新格局。此外，利用公司拥有 的全产业链的优 ...

Core Viewpoint - The company held its 2024 annual performance briefing, addressing investor concerns about its core product, Panlong Qipian, and its strategies to mitigate price reduction risks from centralized procurement [1][2] Group 1: Company Performance and Product Positioning - Panlong Qipian is an exclusive patented traditional Chinese medicine and a Class A product under medical insurance, recognized in multiple national clinical guidelines and textbooks [1] - In the first half of 2024, Panlong Qipian ranked first in market share within the traditional Chinese medicine sector for musculoskeletal and rheumatic diseases, holding an 8.05% market share [1] - The company has developed a strong portfolio of products for rheumatic bone diseases, including Panlong Qipian, Panlong Jiu, and others, enhancing its market presence and competitiveness [1] Group 2: Strategic Initiatives and Future Development - The company plans to deepen evidence-based research on Panlong Qipian, enhance its competitive strategies, and actively develop untapped markets, particularly in county-level areas [2] - Future potential products, such as Xiaer Yanbian Granules and Bone Health Tablets, are expected to exceed one billion in market development, aiming for a dual sales drive in clinical and retail sectors [2] - The company will leverage its full industry chain advantages to strengthen its drug source base and accelerate innovation in traditional Chinese medicine [2]

Group 1 - The core activity involved a charity medical consultation and medicine donation event organized by the Shaanxi Securities Regulatory Bureau and the Shaanxi Listed Companies Association, featuring two pharmaceutical companies, Panlong Pharmaceutical and Kanghui Pharmaceutical [1][2] - Panlong Pharmaceutical emphasized its commitment to public welfare and health, aiming to integrate its corporate social responsibility into its operations by providing medical services and medicines directly to rural communities [1] - Kanghui Pharmaceutical expressed its dedication to improving life quality and human health, planning to continue various public welfare activities and deepen cooperation with local medical institutions [1] Group 2 - The event was a targeted initiative based on an assessment of villagers' health conditions, showcasing the social responsibility of the capital market and the service-oriented culture of the industry [2] - A total donation value of 149,800 yuan (approximately 14.98 million) was made, including 4,417 boxes of medicines and two medical devices, which were donated by the Shaanxi Listed Companies Association [2] - The medical consultation event served over 210 people, with more than 1,400 boxes of donated medicines distributed, including essential products for various health conditions such as gout, cardiovascular issues, and common colds [2]

中泰证券股份有限公司 关于陕西盘龙药业集团股份有限公司 2024 年度持续督导定期现场检查报告 | 保荐人名称：中泰证券股份有限公司 被保荐公司简称：盘龙药业 | | --- | | 保荐代表人姓名：杨圣志 联系电话：010-59013887 | | 保荐代表人姓名：王彦忠 联系电话：010-59013948 | | 现场检查人员姓名：杨圣志 | | 现场检查对应期间：2024 年 1 月 1 日—2024 年 12 月 31 日 | | 现场检查时间：2025 年 4 月 14 日-4 月 16 日、2025 年 4 月 24 日-4 月 27 日 | | 一、现场检查事项 现场检查意见 | | （一）公司治理 是 否 不适用 | | 现场检查手段：查阅公司章程、三会规则及其他内部管理制度、三会运作资料；了解公司 | | 管理层的任职情况；查询公司股权结构及主要股东持股情况；与公司相关人员进行访谈 | | 等。 | | 1、公司章程和公司治理制度是否完备、合规 √ | | 2、公司章程和三会规则是否得到有效执行 √ | | 3、三会会议记录是否完整，时间、地点、出席人员 | | 及会议内容等要件是否齐备，会 ...